Skip to main content

Advertisement

Table 2 Clinicopathologic characteristics of patients based on liver metastatic tumors

From: Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

Characteristic Non-targeted therapy Bev-combined therapy Cet-combined therapy
Metastatic tumors 252 (66.3) 44 (11.6) 84 (22.1)
Primary tumor site
 Right side 36 (14.3) 17 (38.6) 14 (16.7)
 Left side 216 (85.7) 27 (61.4) 70 (83.3)
Primary tumor grade
 G1–2 189 (75.0) 35 (79.5) 50 (59.5)
 G3 63 (25.0) 9 (20.5) 34 (40.5)
Histological subtype of primary tumor
 Non-mucinous 228 (90.5) 42 (95.5) 74 (88.1)
 Mucinous 24 (9.5) 2 (4.5) 10 (11.9)
Primary tumor pT categorya
 pT1–2 31 (12.3) 2 (4.5) 4 (4.8)
 pT3–4 221 (87.7) 42 (95.5) 80 (95.2)
Primary tumor pN categorya
 pN0 106 (42.1) 29 (65.9) 26 (31.0)
 pN1–2 146 (57.9) 15 (34.1) 58 (69.0)
CEA declineb
 Yes 136 (54.0) 35 (79.5) 55 (65.5)
 No 56 (22.2) 7 (15.9) 6 (7.1)
 Unevaluable 60 (23.8) 2 (4.5) 23 (27.4)
Metastases presentation
 Synchronous 208 (82.5) 40 (90.9) 67 (79.8)
 Metachronous 44 (17.5) 4 (9.1) 17 (20.2)
Size of metastases (cm)
 < 2.5 154 (61.1) 15 (34.1) 58 (69.0)
 ≥ 2.5 98 (38.9) 29 (65.9) 26 (31.0)
Resection status of liver metastases
 R0 171 (67.9) 36 (81.8) 48 (57.1)
 R1–2 81 (32.1) 8 (18.2) 36 (42.9)
Duration of preoperative chemotherapyc
 Short duration 109 (43.3) 23 (52.3) 31 (36.9)
 Long duration 143 (56.7) 21 (47.7) 53 (63.1)
Chemotherapy backbone
 Oxa-based 184 (73.0) 29 (65.9) 16 (19.0)
 Iri-based 52 (20.6) 15 (34.1) 66 (78.6)
 Oxa + Iri-based 13 (5.2) 0 (0.0) 2 (2.4)
 Fluoropyrimidine only 3 (1.2) 0 (0.0) 0 (0.0)
TRGd
 1–2 95 (37.7) 21 (47.7) 32 (38.1)
 3 97 (38.5) 15 (34.1) 32 (38.1)
 4–5 60 (23.8) 8 (18.2) 20 (23.8)
  1. All data are presented as number of metastases followed by percentages in parentheses
  2. Bev bevacizumab, Cet cetuximab, CEA carcinoembryonic antigen, Oxa oxaliplatin, Iri irinotecan, TRG tumor regression grade
  3. a According to the Union for International Cancer Control (UICC) staging system (7th edition)
  4. b The CEA decline was based on the comparison between the preoperative CEA and the baseline CEA detection. Because initial CEA levels were unavailable, 30 of 159 patients (85 of 380 available tumors) were not evaluable for CEA variations
  5. c Short duration of preoperative chemotherapy: ≤ 4 cycles for 2-week regimens or ≤ 3 cycles for 3-week regimens; long duration of preoperative chemotherapy: > 4 cycles for 2-week regimens or > 3 cycles for 3-week regimens
  6. d TRG was evaluated as metastases-related analysis